83 related articles for article (PubMed ID: 21321266)
1. PET of αvbeta3-integrin and αvbeta5-integrin expression with 18F-fluciclatide for assessment of response to targeted therapy: ready for prime time?
Beer AJ; Schwaiger M
J Nucl Med; 2011 Mar; 52(3):335-7. PubMed ID: 21321266
[No Abstract] [Full Text] [Related]
2. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent.
Battle MR; Goggi JL; Allen L; Barnett J; Morrison MS
J Nucl Med; 2011 Mar; 52(3):424-30. PubMed ID: 21321268
[TBL] [Abstract][Full Text] [Related]
3. [¹⁸F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3 and α vβ 5 integrins.
Mena E; Owenius R; Turkbey B; Sherry R; Bratslavsky G; Macholl S; Miller MP; Somer EJ; Lindenberg L; Adler S; Shih J; Choyke P; Kurdziel K
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1879-88. PubMed ID: 24973039
[TBL] [Abstract][Full Text] [Related]
4. Imaging of alpha(v)beta(3) expression by a bifunctional chimeric RGD peptide not cross-reacting with alpha(v)beta(5).
Zannetti A; Del Vecchio S; Iommelli F; Del Gatto A; De Luca S; Zaccaro L; Papaccioli A; Sommella J; Panico M; Speranza A; Grieco P; Novellino E; Saviano M; Pedone C; Salvatore M
Clin Cancer Res; 2009 Aug; 15(16):5224-33. PubMed ID: 19671851
[TBL] [Abstract][Full Text] [Related]
5. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
6. Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB.
Monferran S; Skuli N; Delmas C; Favre G; Bonnet J; Cohen-Jonathan-Moyal E; Toulas C
Int J Cancer; 2008 Jul; 123(2):357-364. PubMed ID: 18464290
[TBL] [Abstract][Full Text] [Related]
7. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
Weller M; Nabors LB; Gorlia T; Leske H; Rushing E; Bady P; Hicking C; Perry J; Hong YK; Roth P; Wick W; Goodman SL; Hegi ME; Picard M; Moch H; Straub J; Stupp R
Oncotarget; 2016 Mar; 7(12):15018-32. PubMed ID: 26918452
[TBL] [Abstract][Full Text] [Related]
8. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
[TBL] [Abstract][Full Text] [Related]
9. Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors.
Sharma R; Kallur KG; Ryu JS; Parameswaran RV; Lindman H; Avril N; Gleeson FV; Lee JD; Lee KH; O'Doherty MJ; Groves AM; Miller MP; Somer EJ; Coombes CR; Aboagye EO
J Nucl Med; 2015 Dec; 56(12):1855-61. PubMed ID: 26383153
[TBL] [Abstract][Full Text] [Related]
10. Expression of integrins αvβ3 and αvβ5 and their ligands in primary and secondary central nervous system neoplasms.
Mittelbronn M; Warth A; Meyermann R; Goodman S; Weller M
Histol Histopathol; 2013 Jun; 28(6):749-58. PubMed ID: 23238957
[TBL] [Abstract][Full Text] [Related]
11. In vivo alpha-V beta-3 integrin expression in human aortic atherosclerosis.
Jenkins WS; Vesey AT; Vickers A; Neale A; Moles C; Connell M; Joshi NV; Lucatelli C; Fletcher AM; Spratt JC; Mirsadraee S; van Beek EJ; Rudd JH; Newby DE; Dweck MR
Heart; 2019 Dec; 105(24):1868-1875. PubMed ID: 31422361
[TBL] [Abstract][Full Text] [Related]
12. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis.
Chen X; Park R; Shahinian AH; Tohme M; Khankaldyyan V; Bozorgzadeh MH; Bading JR; Moats R; Laug WE; Conti PS
Nucl Med Biol; 2004 Feb; 31(2):179-89. PubMed ID: 15013483
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin αvβ3 and vascular endothelial growth factor.
Sun X; Ma T; Liu H; Yu X; Wu Y; Shi J; Jia B; Zhao H; Wang F; Liu Z
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1428-39. PubMed ID: 24562646
[TBL] [Abstract][Full Text] [Related]
14. Microglial expression of alphavbeta3 and alphavbeta5 integrins is regulated by cytokines and the extracellular matrix: beta5 integrin null microglia show no defects in adhesion or MMP-9 expression on vitronectin.
Milner R
Glia; 2009 May; 57(7):714-23. PubMed ID: 18985734
[TBL] [Abstract][Full Text] [Related]
15. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
16. Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma.
Skuli N; Monferran S; Delmas C; Favre G; Bonnet J; Toulas C; Cohen-Jonathan Moyal E
Cancer Res; 2009 Apr; 69(8):3308-16. PubMed ID: 19351861
[TBL] [Abstract][Full Text] [Related]
17. Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy?
Rylova SN; Barnucz E; Fani M; Braun F; Werner M; Lassmann S; Maecke HR; Weber WA
J Nucl Med; 2014 Nov; 55(11):1878-84. PubMed ID: 25278514
[TBL] [Abstract][Full Text] [Related]
18. 18F-FPRGD2 PET/CT imaging of integrin αvβ3 in renal carcinomas: correlation with histopathology.
Withofs N; Signolle N; Somja J; Lovinfosse P; Nzaramba EM; Mievis F; Giacomelli F; Waltregny D; Cataldo D; Gambhir SS; Hustinx R
J Nucl Med; 2015 Mar; 56(3):361-4. PubMed ID: 25655629
[TBL] [Abstract][Full Text] [Related]
19. Cell surface overexpression of alphavbeta5 integrin impedes alphavbeta3-mediated migration of the human ovarian adenocarcinoma cell line IGROV1.
Maubant S; Leroy-Dudal J; Carreiras F; Deslandes E; Duigou F; Staedel C; Gauduchon P
Cell Biol Int; 2007 Feb; 31(2):109-18. PubMed ID: 17074516
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of ανβ3-mediated tumor expression with a 99mTc-labeled ornithine-modified RGD derivative during glioblastoma growth in vivo.
Tsiapa I; Loudos G; Fragogeorgi EA; Bouziotis P; Psimadas D; Xanthopoulos S; Paravatou-Petsotas M; Palamaris L; Varvarigou AD; Karnabatidis D; Kagadis GC
Cancer Biother Radiopharm; 2014 Dec; 29(10):444-50. PubMed ID: 25405951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
